Consolidative allogeneic hematopoietic stem cell transplantation after chimeric antigen receptor T-cell therapy for relapsed/refractory B-cell acute lymphoblastic leukemia: who? When? Why?

Table 2 Consolidative allo-HSCT regimen

Register number	Donor type	Cell type	Conditioning therapy	GVHD prophylaxis
ChiCTR-llh-16008711 [26]	17 Haploidentical 7 MUD 3 MSD	/	27 MAC (24 TBI/CY/Ara-C/MeCCNU/±ATG, 3 Bu/CY/Ara-C/MeCCNU/±ATG)	/
NCT01865617 [27]	3 MRD 9 MUD 1 mMURD 1 Haploidentical 5 UCT	13 PBSC 1 BM 5 Cord	14 MAC 2 RIC 3 NMA	5 CNI + MMF 1 CNI + MMF + sirolimus 9 CNI + MTX 3 CNI + MTX + abatacept 1 CNI + MMF + PtCy
NCT02965092 & NCT03366350 [28]	8 MSD 13 haploidentical	16 PBSC 5 PBSC+BM	21 MAC (VP16 + BUCY)	8 CsA/FK506 + MTX 13 FK506 + MTX + MMF + CD25 antibody+ATG
NCT03173417 [30]	16 MSD 9 MUD 50 Haploidentical	/	75 MAC (69 TBI-based for >5y patients, 6 Bu-based for ≤5y patients)	75 CsA + MTX + MMF

Ara-C cytarabine, ATG anti-thymocyte globulin, BM bone marrow, Bu Busulfan, BUCY busulfan and cyclophosphamide, CNI calcineurin inhibitor, CsA Cyclosporine, CY cyclophosphamide, FK506 tacrolimus, MAC myeloablative conditioning, MeCCNU methyl-CCNU-semustine, MMF mycophenolate mofetil, mMURD mismatched unrelated donor, MRD matched related donor, MSD matched sibling donor, MTX methotrexate, MUD matched unrelated donor, NMA nonmyeloablative conditioning, PBSC peripheral blood stem cell, PtCy posttransplant cyclophosphamide, RIC reduced-intensity conditioning, TBI total body irradiation, UCT umbilical cord transplant, VP16 etoposide

ISSN: 2050-7771